Cost and threshold analysis of an HIV/STI/hepatitis prevention intervention for young men leaving prison: Project START

AIDS and Behavior

Volumn 17, Issue 8, 2013, Pages 2676-2684

  Johnson, A P ^a   MacGowan, R J ^b   Eldridge, G D ^c   Morrow, K M ^d   Sosman, J ^e   Zack, B ^f   Margolis, A ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF ALASKA ANCHORAGE   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f The Bridging Group   (United States)

Author keywords

AIDS; Cost; HIV; Prevention; Prison

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PREVENTIVE HEALTH SERVICE; PRISONER; PROSPECTIVE STUDY; SEXUALLY TRANSMITTED DISEASE; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; CALIFORNIA; COST-BENEFIT ANALYSIS; HEPATITIS; HIV SEROPOSITIVITY; HUMANS; MALE; MISSISSIPPI; PREVENTIVE HEALTH SERVICES; PRISONERS; PROSPECTIVE STUDIES; RHODE ISLAND; SEXUALLY TRANSMITTED DISEASES; WISCONSIN;

EID: 84885427480     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-0096-7     Document Type: Article

References (44)

1. West H, Minton T, Simmons S, Snell T. Prisoners at year end 2009 - advance counts. Washington DC: US Department of Justice Officer of Justice Programs; 2010.
2. Maruschak L, Beavers R. HIV in prisons, 2007-2008. Washington DC: US Department of Justice Office of Justice Programs; 2009.
3. Hogben M, St. Lawrence J, Eldridge GD. Sexual risk behavior, drug use, and STD rates among incarcerated women. Women Health. 2001;34:63-78.
4. Morris RE, Harrison EA, Knox GW, Tromnhauser E, Marquis DK, Watts LL. Health risk behavioral survey from 39 juvenile correctional facilities in the United States. J Adolesc Health. 1995;17:334-344.
5. Margolis AD, MacGowan RJ, Grinstead O, et al. Unprotected sex with multiple partners: implications for HIV prevention among young men with a history of incarceration. Sex Transm Dis. 2006;33(3):175-80.
6. Morris RE, Baker CJ, Valentine M, Pennisi AJ. Variations in HIV risk behaviors of incarcerated juveniles during a four-year period: 189-1992. J Adolesc Health. 1998;23:39-48.
7. Teplin LA, Mericle AA, McClelland GM, Abram KM. HIV and AIDS risk behaviors in juvenile detainees: implications for public health policy. Am J Public Health. 2003;93:906-12.
8. Grinstead OA, Faigeles B, Comfort M, Seal DW, Nealey-Moore J, Belcher L, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;4(2):63-80.
9. Belenko S, Langley S, Crimmins S, Chaple M. HIV risk behaviors, knowledge, and prevention education among offenders under community supervision: a hidden risk group. AIDS Educ Prev. 2004;16:367-85.
10. MacGowan RJ, Margolis AD, Gaiter J, et al. Predictors of risky sex of young men after release from prison. Int J STD AIDS. 2003;14:519-23.
11. Morrow KM, Eldridge GD, Nealey-Moore J, Grinstead OA, The Project Start Study Group. HIV, STD, and hepatitis risk in the week following release from prison: an event-level analysis. J Correct Health Care. 2007;13(1):27-38.
12. Okie S. Sex, drugs, prisons, and HIV. N Engl J Med. 2007;356(2):105-8.
13. Burattini MN, Massad E, Rozman M, Azevedo RS, Carvalho HB. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000;34(5):431-6.
14. Mahon N. New York inmates' HIV risk behaviors: the implications for prevention policy and programs. Am J Public Health. 1996;86:1211-5.
15. Bryan A, Robbins RN, Ruiz MS, O'Neill D. Effectiveness of an HIV prevention intervention in prison among African Americans, Hispanics, and Caucasians. Health Educ Behav. 2006;33(2):154-77.
16. Dolan KA, Bijl M, White B. HIV education in a Siberian prison colony for drug dependent males. Int J Equity Health. 2004;3:7.
17. Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33-41.
18. Springer SA, Altice FL. Managing HIV/AIDS in correctional settings. Curr HIV/AIDS Rep. 2005;2(4):165-70.
19. Gorsky RD. A method to measure the costs of counseling for HIV prevention. Public Health Rep. 1996;111(Suppl 1):115-22.
20. Varghese B, Peterman TA. Cost-effectiveness of counseling and testing in US prisons. J Urban Health. 2001;78:304-12.
21. Varghese B, Peterman TA, Holtgrave DR. Cost-effectiveness of counseling and testing and partner notification: a decision analysis. AIDS. 1999;13(13):1745-51.
22. Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 States - Advancing HIV prevention demonstration project, 2003-2006. Sex Transm Dis. 2009;36(2):S5-8.
23. Kraut-Becher JR, Gift T, Haddix A, Irwin K, Greifinger R. The cost-effectiveness of universal screening for chlamydia and gonorrhea in United States jails. J Urban Health. 2004;81:453-71.
24. Pisu M, Meltzer MI, Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine. 2002;21(3-4):312-21.
25. Warren E, Viney R, Shearer J, Shanahan M, Wodak A, Dolan K. Value for money in drug treatment: economic evaluation of prison methadone. Drug Alcohol Depend. 2006;84(2):160-6.
26. Wolitski RJ, Project START Writing Group. Relative efficacy of a multisession sexual risk-reduction intervention for young men released from prisons in 4 States. Am J Public Health. 2006;96(10):1854-61.
27. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
28. Holtgrave DR. Handbook for the economic evaluation of HIV prevention programs. New York: Plenum Press; 1998.
29. Trentacoste ND, Holtgrave DR, Collins C, Abdul-Quader A. Disseminating effective behavioral interventions for HIV prevention: a cost analysis of a risk-reduction intervention for drug users. J Public Health Manag Pract. 2004;10:130-9.
30. Grinstead OA, Eldridge G, MacGowan RJ, et al. An HIV, STD, and hepatitis prevention program for young men leaving prison: project START. J Correct Health Care. 2008;14(3):183-96.
31. Grinstead OA, Seal DW, Wolitski RJ, et al. HIV and STD testing in prisons: perspectives of in-prison service providers. AIDS Educ Prev. 2003;15(6):547-60.
32. Seal DW, Belcher L, Morrow K, et al. A qualitative study of substance use and sexual behavior among 18- to 29-year-old men while incarcerated in the United States. Health Educ Behav. 2004;3(6):775-89.
33. Seal DW, Eldridge GD, Kacanek D, Binson D, MacGowan RJ, Project START Study Group. A longitudinal, qualitative analysis of the context of substance use and sexual behavior among 18- to 29-year-old men after their release from prison. Soc Sci Med. 2007;65(11):2394-406.
34. Seal DW, Margolis AD, Sosman J, Kacanek D, Binson D, Project START Study Group. HIV and STD risk behavior among 18- to 25-year old men released from US prisons: provider perspectives. AIDS Behav. 2003;7(2):131-41.
35. Seal DW, Margolis AD, Morrow KM, et al. Substance use and sexual behavior during incarceration among 18- to 29-year old men: prevalence and correlates. AIDS Behav. 2008;12:27-40.
36. Sosman JM, MacGowan RJ, Margolis AD, et al. Screening for sexually transmitted diseases and hepatitis in 18-29-year-old men recently released from prison: feasibility and acceptability. Int J STD AIDS. 2005;16:117-22.
37. Buck JM, Morrow KM, Margolis A, et al. Hepatitis B vaccination in prison: the perspectives of formerly incarcerated men. J Correct Health Care. 2006;12(1):12-23.
38. Kacanek D, Eldridge GD, Nealey-Moore J, et al. Young incarcerated men's perceptions of and experiences with HIV testing. Am J Public Health. 2007;97(7):1209-15.
39. MacGowan RJ, Eldridge G, Sosman JM, et al. HIV counseling and testing of young men in prison. J Correct Health Care. 2006;12(3):203-13.
40. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimate for use in economic evaluation of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(1):54-62.
41. Hutchison AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43:451-7.
42. Pinkerton SD, Johnson-Masotti AP, Holtgrave DR, Farnham PG. Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV. AIDS. 2001;15:917-28.
43. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-7.
44. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.